Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics (PTCT) provides critical updates through this centralized news resource for investors and industry stakeholders. Track official announcements spanning clinical trial progress, regulatory milestones, and strategic partnerships in rare disease therapeutics.
Access timely updates on PTCT's small molecule developments, gene therapy advancements, and financial disclosures. Our curated feed ensures comprehensive coverage of material events including FDA submissions, research collaborations, and commercialization efforts.
This repository features verified press releases covering:
• Clinical trial results for neuromuscular and oncology programs
• Regulatory filings and orphan drug designations
• Strategic alliances with research institutions
• Financial performance and earnings communications
Bookmark this page for direct access to PTCT's evolving developments in post-transcriptional control therapeutics. Monitor breakthrough innovations addressing Duchenne muscular dystrophy, genetic disorders, and underserved patient populations.
PTC Therapeutics reported total revenue of $699 million for 2022, a 30% year-over-year growth, or $740 million at constant exchange rates, a 37% increase. The company reaffirmed its 2023 guidance, expecting total revenue between $940 million and $1 billion. Key products include the Duchenne muscular dystrophy franchise, generating $507 million, and new therapies advancing in clinical trials. Notably, net loss for Q4 2022 was $170.9 million, compared to $143.3 million in Q4 2021. Cash and marketable securities fell to $410.7 million from $773.4 million in 2021.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in three upcoming investor conferences. The events include the Raymond James 44th Annual Institutional Investor Conference on March 6 at 8:05 a.m. EST, the Cowen 43rd Annual Health Care Conference on March 7 at 12:50 p.m. EST, and the Barclays Global Healthcare Conference on March 14 at 8:00 a.m. EST. Each presentation will be webcast live and archived on the company's Events and Presentations page for 30 days. PTC specializes in developing innovative medicines for rare disorders.
PTC Therapeutics (NASDAQ: PTCT) will host a webcast conference call on February 21, 2023, at 4:30 PM ET to report its fourth quarter and full year 2022 financial results. The call aims to provide an update on the company's business and future outlook. Interested participants can register here for dial-in information. The call will also be accessible via the PTC Investor website and archived for 30 days for those unable to attend live.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has received the 2023 EURORDIS Black Pearl Company Award for Innovation, recognizing its 25-year commitment to rare disease research and treatment. The award celebrates organizations making significant advancements in the development of therapies for rare diseases.
CEO Stuart W. Peltz highlighted the importance of this recognition as PTC marks its quarter-century serving the rare disease community. The award ceremony is scheduled for February 21 in Brussels, coinciding with Rare Disease Day, which aims to raise awareness about rare diseases globally.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced its participation in the SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 a.m. EST. The company will present a comprehensive overview of its operations and strategic focus. A live webcast of the presentation will be available on PTC's Events and Presentations page and will be archived for 30 days. PTC is dedicated to developing innovative treatments for patients with rare disorders, aiming to maximize access to transformative medicines. For further details, visit www.ptcbio.com.
PTC Therapeutics (NASDAQ: PTCT) announced that the National Institute for Health and Care Excellence (NICE) has recommended Translarna™ (ataluren) for reimbursement within the National Health Service (NHS) in England and Wales. This decision makes Translarna the only approved treatment for patients aged 2 and older with nonsense mutation Duchenne muscular dystrophy who can walk. The NICE recommendation is based on clinical trials showing Translarna's effectiveness in slowing disease progression and improving outcomes. This marks a significant milestone for patients and reflects PTC's ongoing commitment to access for effective treatments.
PTC Therapeutics (PTCT) announced the launch of its ninth STRIVE™ awards program aimed at funding initiatives for the Duchenne Muscular Dystrophy (Duchenne) community. Submissions are due by March 17, 2023, with projects focusing on Innovation and Transition to Adulthood. Since its inception in 2015, STRIVE has supported 39 initiatives across 20 countries, addressing the needs of Duchenne patients who now live longer due to improved treatments. This year’s recipients will be announced in September, continuing PTC's 25-year commitment to support the Duchenne community.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on January 5, 2023, the approval of non-statutory stock options for 39,585 shares and 13,045 restricted stock units (RSUs) for 33 new employees as a part of their employment compensation. This follows the NASDAQ inducement grant exception guidelines. The stock options have an exercise price of $39.42 per share, vesting over four years, while the RSUs also vest over a four-year period. These grants are designed to attract talent and align new hires’ interests with the company's long-term goals.
PTC Therapeutics reported a 2022 total revenue of approximately $710 million, showing over 30% year-over-year growth. The company projects 2023 total revenue guidance between $940 million and $1 billion. Significant corporate milestones include the approval of Upstaza™ for AADC deficiency and the initiation of several clinical trials. The unaudited net product revenue in 2022 reached $535 million, with guidance for DMD franchise revenue in 2023 between $545 million and $565 million.
PTC Therapeutics, based in South Plainfield, N.J., will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 a.m. PST/10:30 a.m. EST.
The presentation can be accessed via a live webcast on the company’s Investor section and will be archived for 30 days. PTC focuses on developing medicines for rare disorders, aiming to provide access to transformative treatments for patients with unmet medical needs.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
